Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7
November 22, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 06, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
Total 3Q 2023 product revenue of $57.8 million, representing 244% year-over-year growth Auvelity® 3Q 2023 net product sales of $37.7 million, representing 36% quarter-over-quarter growth Sunosi® 3Q...
Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023
November 02, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Present at Upcoming Investor Conferences
October 31, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference
October 24, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
October 11, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6
October 10, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week
October 02, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
September 21, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...